Cochrane Abstracts
Anti‐angiogenic therapy for high‐grade glioma
There's more to see -- the rest of this topic is available only to subscribers.
Citation
"Anti‐angiogenic Therapy for High‐grade Glioma." Cochrane Abstracts, John Wiley & Sons, Inc, 2025. Evidence Central, evidence.unboundmedicine.com/evidence/view/Cochrane/437777/all/Anti‐angiogenic_therapy_for_high‐grade_glioma.
Anti‐angiogenic therapy for high‐grade glioma. Cochrane Abstracts. John Wiley & Sons, Inc; 2025. https://evidence.unboundmedicine.com/evidence/view/Cochrane/437777/all/Anti‐angiogenic_therapy_for_high‐grade_glioma. Accessed March 26, 2025.
Anti‐angiogenic therapy for high‐grade glioma. (2025). In Cochrane Abstracts. John Wiley & Sons, Inc. https://evidence.unboundmedicine.com/evidence/view/Cochrane/437777/all/Anti‐angiogenic_therapy_for_high‐grade_glioma
Anti‐angiogenic Therapy for High‐grade Glioma [Internet]. In: Cochrane Abstracts. John Wiley & Sons, Inc; 2025. [cited 2025 March 26]. Available from: https://evidence.unboundmedicine.com/evidence/view/Cochrane/437777/all/Anti‐angiogenic_therapy_for_high‐grade_glioma.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Anti‐angiogenic therapy for high‐grade glioma
ID - 437777
BT - Cochrane Abstracts
UR - https://evidence.unboundmedicine.com/evidence/view/Cochrane/437777/all/Anti‐angiogenic_therapy_for_high‐grade_glioma
PB - John Wiley & Sons, Inc
DB - Evidence Central
DP - Unbound Medicine
ER -
